Acute ischaemic stroke is a leading cause of death in Canada and should be a priority in health care. This paper defines acute ischaemic stroke and provides current statistics, economic costs, risk factors, treatments, and management options. A gap between current practice and literature is identified. Specific treatments of anticoagulant and antiplatelet therapy are explored through systematic reviews, clinical trials, and national guidelines. 
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with minor disability, 40% are left with moderate to severe impairment, and 10% are severely disabled and require long-term care. Disabilities may range from slight weakness of a hand to permanent hemiparesis. A stroke survivor has a 20% chance of restroke within two years (Health Canada, 2006) . This paper will deal specifically with AIS as it is the most common type of stroke.
Financial Cost of Stroke
Stroke costs the Canadian economy 2.7 billion dollars per year in physician services, hospital costs, lost wages, and lost productivity, with an average of$27,500 per stroke (Heart and Stroke Foundation, 2008) . Stroke cost in British Columbia is estimated to be greater than $327 million annually (HSFBC&Y, 2005) . Lindsay et al. (2008) contend that organized stroke care over a 20-year period could prevent 160,000 strokes; a projected $8 billion in savings to the Canadian health care system.
Risk Factors for Stroke
After age 55, the risk of stroke doubles every 10 years and more women than men die from stroke at all ages (Health Canada, 2006; Heart and Stroke Foundation, 2007) . Some pre-existing medical conditions as well as some lifestyle factors can put people at a higher risk for stroke. Risk factors for stroke include hypertension, diabetes, hyperlipidemia, atrial fibrillation, atherosclerosis, recent myocardial infarction, family, and/or personal history of heart disease (Harrison's Practice, 2007; Health Canada, 2006) . Other risk factors include cigarette smoking, acquired immune deficiency syndrome (AIDS), recreational drug use, and heavy alcohol consumption (Center for Disease Control and Prevention, 2007) .
Causes of Stroke
While hemorrhagic or 'bleeding' stroke accounts for 15-20 % of total strokes, acute ischaemic stroke (AIS) accounts for 80-85% of all strokes. AIS is caused by emboli, thrombus, or systemic hypoperfusion that blocks an artery leading to the brain (Granitto, 2008) . Embolic causes due to atrial fibrillation, patent foramen ovale, and low ejection fraction account for 45% of ischaemic strokes. Thrombus due to plaque buildup and narrowed arteries accounts for 30% of ischaemic strokes. The remaining 25% of ischaemic strokes are attributable to systemic hypoperfusion, hypercoagulable states, and cryptogenic causes (Granitto ) . With the major proportion of strokes being ischaemic, it is prudent for this project to determine the best evidence for treating AIS .
Clinical Presentation of Stroke
The usual clinical presentation of AIS include neurologic impairment such as transient blindness, diplopia, dizziness, headache, sensory deficiencies, speech problems, motor difficulties, and weakness or numbness (Heart and Stroke Foundation of Canada, 2007) . Severe impairment may include a loss of consciousness after the event, coma, or death (Tierney, 2007) . Generally, the greater or larger the cerebral vessel involved, the greater the risk of morbidity and mortality.
Diagnosing Stroke
Emergency non-contrast head computed tomography (CT) is mandatory for distinguishing ischaemic from hemorrhagic stroke. A head CT scan is a crucial diagnostic tool in the evaluation of this cause of stroke, since patients with AIS may be eligible to receive thrombolytics therapy, while patients with hemorrhagic stroke are best treated with a completely different therapeutic pathway (Becker, 2006) . This paper will focus on the treatment of AIS with specific interest in anticoagulant and antiplatelet therapy. Treatment of AIS with thrombolytics will be briefly discussed due to the importance of the medication in treating AIS.
Treatment of AIS
The guiding principle in AIS treatment is the phrase Time is Brain. This refers to the need to act quickly because brain tissue is lost with every minute that passes. Treatment of AIS includes three different medications: thrombolytics, anticoagulants, and antiplatelets. This paper will define the three classes of medications, however, the focus will be on antiplatelet therapy versus anticoagulant therapy because there appears to be a considerable discrepancy between individual practice and recommended guidelines with regard to the two treatments. Granitto (2008) asserts that to date, the use of intravenous tissue plasminogen activator tPA is the sole thrombolytic agent approved for use in patients with AIS. This drug class is commonly referred to as ' clot buster' medication and has been used since 1996.
Thrombolytics
Dissolving the clot will reduce damage to the brain, therein reducing the effects of the stroke and decreasing permanent disability (AHA, 2008) . Tierney (2007) states that tPA decreases the risk of disability by 30% in patients who receive the drug within 3 hours of onset of AIS.
Effective and rapid treatment of AIS increases quality of life and decreases the mortality rate.
The use of tP A carries the risks of intracerebral hemorrhage and angioedema with possible airway compromise, all which are serious and life threatening side effects . TP A should therefore only be used within the confines of stroke guidelines, and initiated only after AIS is confirmed by a head CT scan. Since ischaemic stroke must be accurately diagnosed by CT scan, many patients are unable to receive the clot busting therapy due to time constraints. The 3 hour time frame for use oftPA limits its use in rural and remote areas of British Columbia. In addition to time, there are many inclusion criteria that must be met for a patient with AIS to receive tP A such as medical history and current illnesses. TP A has substantial costs including the medication itself and the specially trained medical/nursing staff required to administer it.
Anticoagulants
Anticoagulant drug therapies include heparin, low molecular weight heparin (LMWH), and warfarin. Warfarin reduces the synthesis of clotting factors by depleting the body's store of vitamin K and takes 48 to 72 hours to become therapeutic . Warfarin causes twice as many hemorrhages as aspirin, particularly in patients with a history ofbleeding or genetic disorder and in elderly patients (Hankey, 2005) . Warfarin has a narrow therapeutic window, requires frequent dosing changes, continuous monitoring, and is affected by numerous drug and food interactions (Hankey) . Heparin and LMWH prevent blood clotting by potentiating the action of antithrombin therein inactivating thrombin and preventing the conversion of fibrinogen to fibrin (Valentine & Hull, 2007) . While the heparins also have a narrow therapeutic window, and require twice daily injections, the duration of action is about 12 hours compared to 3-5 days for warfarin. However, like warfarin, the heparins also have similar bleeding complications, which could offset any benefits. Hemorrhagic stoke will develop if an AIS is treated with warfarin or heparin 50% more frequently than if treated with aspirin (Berge & Sandercock, 2002) .
Antiplatelets
Anti platelet drug therapies include aspirin and thienopyridine derivatives ( clopidogrel and ticlopidine). Aspirin, clopidogrel, and ticlopidine block prostaglandin synthetase action which prevents formation of the platelet aggregating substance thromboxane (Lexi-Comp, 2008a; Lexi-Comp, 2008b ) . Aspirin has been used for centuries for medicinal purposes and is also quite inexpensive compared to newer antiplatelet drugs. Aspirin is easy to administer and continuous monitoring is not required for patients who receive this medication. Aspirin is not without potential side effects, which include allergic reactions, upper gastrointestinal upset, gastrointestinal bleeding, and rash (Hankey, 2005) . However, the side effects of the theinopyridine derivatives are greater in severity compared to those occurring with aspirin and include hemorrhage, diarrhea, rash, and neutropenia (Hankey) . Current Canadian and
American clinical practice guidelines state that anticoagulant therapy is not recommended for AIS and that antiplatelet therapy using aspirin should be initiated immediately after confirmation of AIS by computed tomography (CT) scan Canadian Stroke Strategy, 2006) .
Management of AIS
Physicians have used anticoagulants to treat patients with AIS for over 50 years, yet despite its longstanding and widespread use, anticoagulant therapy is the subject of much debate . Adams et al. assert that disagreements exist regarding the usefulness of emergency anticoagulation, the best agent to administer, the preferred route of administration, use of a bolus dose to initiate treatment, the level of anticoagulation required, and the duration of treatment. Physicians often erroneously prescribe anticoagulants to patients with recent stroke in an effort to prevent early recurrent stroke and to improve neurological outcomes (Adams et al.) . Nurse Practitioner Stroke Guidelines assert that early anticoagulant therapy does not decrease the risk of neurological worsening (Granitto, 2008) .
In the past decade, guidelines for stroke management have included recommendations on medication use in AIS . These recommendations have changed over the years to incorporate new research findings. Because health care providers continue to prescribe both anticoagulant and antiplatelet therapy for AIS, the current evidence on these therapies merits review.
Study Question
The study question explored in this project is: In patients with acute ishaemic stroke, does antiplatelet therapy as compared to anticoagulant therapy reduce the incidence of restroke and mortality? The patient population consists of people diagnosed with AIS. The intervention of interest is the use of anti platelet therapy compared with anticoagulant therapy. The outcome of interest is which group of patients has had a more positive outcome, specifically, reduced incidence of restroke and decreased mortality.
Literature Review
Sources and Research Processes
Databases used to find evidence to address the question include: Cochrane Database of Systematic Reviews (CDSR), National Guidelines Clearinghouse (NGC), Cumulated
Index ofNursing and Allied Health Literature (CINAHL), MEDLINE, Science Direct, Pubmed, Ovid, Blackwell Synergy, Evidence-based Medicine (EBM) reviews, and
UpToDate. The key words used included: acute ishaemic stroke, antiplatelet, anticoagulant, aspirin and stroke, stroke nursing care, antiplatelet$ and anticoagulant$, stroke prevention, ishaemic stroke and study$, acute ishaemic stroke and trials, cerebrovascular accident, vascular infarct, evidence and prevention, and stroke and guidelines. Inclusion criteria were patients diagnosed with AIS and treated with either anticoagulant, antiplatelet therapy, or combination therapy. The patients in the studies included men and women of varying ethnicities and ages. The systematic reviews were chosen because the reviewers independently selected studies for inclusion, assessed the quality of trials, and extracted the data. The search resulted in three single studies and trials (a RCT, a multi-centre trial, and a case cross-over study) totaling 4,900 patients, four systematic reviews totaling 104,160
patients, and six national guidelines for review and analysis.
Single Studies and Trials
Randomised controlled trials and observational studies provide complimentary evidence to the more powerful systematic review (Barton, 2000) . However, in a multi-centre trial involving 1809 African-American patients diagnosed with stroke, within 90 days of onset, in over 60 cities, aspirin 650 mg was found to be as effective as ticlopidine 500 mg in preventing restroke (Gorlick, 2003) . The potential for serious side effects was found in the patients receiving ticlopidine, therefore outweighing the benefits of administering the medication. Hass et al. ' s ( 1989) RCT involving 3069 patients diagnosed with recent transient or mild persistent focal cerebral or retinal ischaemia compared ticlopidine 500 mg to aspirin 1300 mg. Hass et al. found ticlopidine to be only 2 percent more effective than aspirin for preventing restroke or death in the following three years.
However, the study also found that the side effects ofticlopidine were doubled in comparison to those of aspirin. Noted in this study are the large dose of aspirin and the age of the study. While the above three studies are not as credible on their own as are systematic reviews and national guidelines, the findings are similar to the fmdings of the more credible evidence and are useful in the context of this paper. They were chosen for this project because they address the pressing study question, were in peer reviewed journals, and are examples of well done studies. Evidence from the above studies and trials clearly determines that aspirin should be administered instead of other antiplatelet medications, however, the question of appropriate aspirin dosage remains. While these single studies and trials are included in systematic reviews and national guidelines, they are also valuable as evidence to support individual health care providers as they search for evidence-based provision of care to patients with AIS.
Systematic Reviews
Systematic reviews of randomized controlled trials are "traditionally the gold standard for judging the benefits of treatments, mainly because it is conceptually easier to attribute any observed effect to the treatment being compared" (Barton, 2000) . In the following four systematic reviews, one examines the use of anti platelet therapies clopidogrel and ticlopidine compared to aspirin for the prevention of AIS . The second examines the anticoagulant therapy of unfractionated and low molecular weight heparin compared to aspirin. The third examines the anticoagulants heparinoids and warfarin compared to aspirin.
The fourth compares patients given aspirin versus no aspirin therapy. were found to be slightly more effective than aspirin in preventing stroke in high risk patients, however, the side effects of skin rash and diarrhea increased with clopidogrel (30%) and ticlopidine (>60%). Neutropenia was seen in patients who were administered ticlopidine.
Given the cost comparison and the side effects of the theinopyridines compared to aspirin, aspirin administration is clearly the first choice in treating patients with AIS.
Berge & Sandercock's (2002) systematic review of 16, 558 patients in four RCTs compared unfractionated heparin (UFH) with low molecular weight heparin (LMWH).
Aspirin was used as a control in all trials however, and no specific dose of aspirin was They found that aspirin (160 mg -300 mg) given within 48 hours of stroke onset reduced the risk of restroke equivalent to 7 per 1000 patients at a six month follow up compared to patients not given aspirin. They concluded that aspirin reduces the risk of restroke without major risk of hemorrhagic complications and improves long term outcome. Sandercock et al.
found that mortality was reduced equivalent to 13 patients per 1000 for patients allocated to aspirin. This systematic review is different from the previous ones in that aspirin and aspirin dosage is the only agent studied, most likely due to the fact that aspirin has been the presumed treatment for AIS . Of major importance in this systematic review is the dosage of aspirin recommended, which is a range of 160-300 mg.
Clinical Practice Guidelines
Fletcher (2007) states that clinical practice guidelines (CPGs) are the new reality in medicine and that CPGs are "recommendations for clinicians about the care of patients with specific conditions .. . based on the best available research evidence and practice experience".
CPGs contain two parts, beginning with the foundation of a systematic review of the current research evidence-based on a specific clinical question which is focused on the strength of evidence on which clinical decision making for the particular condition is based. The second part, "which involves both the evidence and the value judgments, is a set of recommendations for how patients with that condition should be managed, everything else being equal" (Fletcher) . The purpose of a CPG is to guide and help the health care provider take better care of patients. CPGs are suggestions for care, rather than rules, and there will always be patients who require independent management. However, it is crucial to critique and recognise credible guidelines because thousands of guidelines, which vary in quality have been published. Fletcher states that the hallmarks for credible guidelines can be recognized by several easily identifiable characteristics which include: expertise, evidencebased, broad-based, regency, imprimatur, implementation, and renew (Appendix A). Fletcher also defines the criteria for reporting clinical practice guidelines (Appendix B).
National Guideline Clearinghouse
The National Guideline Clearinghouse (NGC) web site is maintained by the United
States Federal Agency for Healthcare Quality in conjunction with the American Medical
Association and the American Association of Health Plans. The NGC database houses guidelines from most major medical organizations but does not include every guideline (Fletcher, 2007) . The NGC does not develop, produce, approve, or endorse the guidelines represented on the website. All guidelines on the website "are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, healthcare organizations or plans, and similar entities" (NGC, 2007) .
The following four guidelines from NGC state specifically the appropriate use and dose of aspirin, and discuss other antiplatelet and anticoagulant therapies. Anderson et al. 
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The American Stroke Association (ASA) is a division of the American Heart Association and is dedicated to improving stroke prevention, treatment, and rehabilitation therapy, research, education, advocacy, and the development of scientifically based standards and guidelines (Acker, et al. 2007 ). The ASA developed a multidisciplinary Task Force that determined that there is a fragmented approach to care which currently exists and thereby poses significant obstacles to reducing the morbidity and mortality of stroke.
The American Heart and Stroke Association (2007) evidence, clinical practice guidelines, meta-analysis, case reports, and journal reviews to make best recommendations.
Discussion
Evidence in the literature review clearly demonstrates that there is no benefit in using anticoagulant therapy over antiplatelet therapy in AIS prevention or treatment. In fact,
anticoagulant therapy for patients with AIS is not recommended because anticoagulants cause more harm than benefit. Aspirin 160 -325 mg/day for patients with acute ischaemic stroke is the evidence-based recommendation emerging from the literature. Basically, the only clinical questions remaining are regarding the best loading does of aspirin ( 160mg or 325mg) to treat AIS, and the daily dose of aspirin (50mg or 325mg) to prevent restroke.
Implications for Practice
Best practices are not consistently applied to all people diagnosed with AIS resulting in a significant gap between what should be done and what is actually being done to provide quality care to Canadians (CSS). The major implication for practice within the primary health care setting is that the use of aspirin should be the preferred for treatment and prevention of acute ishaemic stroke and restroke. Daily aspirin can be used in primary, secondary, and tertiary health prevention of acute ischaemic stroke. Usual daily prophylactic dosage is 50-325 mg depending on the patient's tolerance and the clinical situation (Gray, 2003) . Best practices that include these recommendations for AIS care have been developed and are in the process of being implemented in Canada and British Columbia.
Canadian and British Columbia Stroke Strategies
The The CSS recommendations are evidence-based and meet the criteria for credible guidelines as defined by Fletcher (2007) . Further investigation in identifying and choosing appropriate interventions that will overcome the barriers to implementing new evidence-based clinical practice guidelines would merit investigation.
Conclusion.
Acute ishaemic stroke is a significant health concern for both health care practitioners and patients in Northern Health Authority. While there is an identified gap between current theory and practice of the administration of anti platelet versus anticoagulant therapy, substantial evidence-based research has demonstrated best treatment for patients with AIS.
The research evidence recommends the administration of aspirin 160 mg-325 mg over other antiplatelet agents, and recommends against anticoagulant therapy for the treatment of AIS. Implementing aspirin therapy in the prevention and treatment of AIS has considerable economic clinical and economic benefits in Northern Health. Additionally, it is essential for primary health care providers to develop or follow clinical practice guidelines based on research to support the best possible patient care. FNPs can play a significant role in this regard in the primary care team. FNPs emphasize health promotion and disease prevention in primary, secondary, and tertiary care.
